# A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

> **NCT06469008** · PHASE1 · RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 21 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinomas
- Solid Tumor

## Interventions

- **DRUG:** BL-B16D1

## Key facts

- **NCT ID:** NCT06469008
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-27
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06469008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06469008, "A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06469008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*